Drug Trial Radar · NCT04557800
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
186
Actual
Start
Nov 16, 2017
Primary completion
Feb 19, 2021
Study completion Feb 19, 2021
Sponsor
- Lead sponsor
- Denali Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), multiple ascending dose (MAD), and 28-day safety study of orally administered DNL151 in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
DNL151Drug
oral dose(s)
PlaceboDrug
oral dose(s)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) including serious adverse events (SAEs), and discontinuations due to TEAEsTime frame: Up to 42 days
- PK parameter: Maximum observed concentration (Cmax) of DNL151 in plasmaTime frame: Up to 42 days
- PK parameter: Time to maximum observed concentration (Tmax) of DNL151 in plasmaTime frame: Up to 42 days
- PK parameter: The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of DNL151 in plasma (single dosing only)Time frame: Up to 42 days
- PK parameter: Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of DNL151 in plasmaTime frame: Up to 42 days
- PK parameter: The area under the concentration-time curve over a dosing interval (AUC0-τ) of DNL151 in plasma (multiple dosing only)Time frame: Up to 42 days
- PK parameter: Apparent terminal elimination half-life (t1/2) of DNL151 in plasmaTime frame: Up to 42 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
PRA Health Sciences, Van Swietenlaan
Groningen, Netherlands
Centre for Human Drug Research
Leiden, South Holland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.